{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fazaclo&page=3",
    "query": {
      "intervention": "Fazaclo",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 63,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fazaclo&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fazaclo&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T03:59:46.028Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06174116",
      "title": "Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizo Affective Disorder"
      ],
      "interventions": [
        {
          "name": "Lumateperone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Massachusetts, Worcester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2024-04-02",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-11-17T03:59:46.028Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06174116"
    },
    {
      "nct_id": "NCT00169026",
      "title": "Alcoholism and Schizophrenia: Effects of Clozapine",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Dual Diagnosis",
        "Schizoaffective Disorder",
        "Psychotic Disorder",
        "Substance Abuse",
        "Alcohol Abuse"
      ],
      "interventions": [
        {
          "name": "Clozapine versus typical (conventional) and atypical antipsychotic medications",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "19 Years to 65 Years"
      },
      "enrollment_count": 64,
      "start_date": "1999-05",
      "completion_date": "2004-01",
      "has_results": false,
      "last_update_posted_date": "2018-03-14",
      "last_synced_at": "2026-11-17T03:59:46.028Z",
      "location_count": 1,
      "location_summary": "Jamaica Plain, Massachusetts",
      "locations": [
        {
          "city": "Jamaica Plain",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00169026"
    },
    {
      "nct_id": "NCT00794963",
      "title": "Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metabolic Syndrome"
      ],
      "interventions": [
        {
          "name": "Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan",
          "type": "DRUG"
        },
        {
          "name": "As selected by community physician",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "19 Years to 79 Years"
      },
      "enrollment_count": 8,
      "start_date": "2008-11",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2015-04-15",
      "last_synced_at": "2026-11-17T03:59:46.028Z",
      "location_count": 1,
      "location_summary": "Glen Oaks, New York",
      "locations": [
        {
          "city": "Glen Oaks",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00794963"
    },
    {
      "nct_id": "NCT00337350",
      "title": "Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2003-09",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2015-05-08",
      "last_synced_at": "2026-11-17T03:59:46.028Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00337350"
    },
    {
      "nct_id": "NCT04580134",
      "title": "CLOZAPINE Response in Biotype-1",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Bipolar 1 Disorder"
      ],
      "interventions": [
        {
          "name": "clozapine",
          "type": "DRUG"
        },
        {
          "name": "risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 524,
      "start_date": "2022-03-01",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-11-17T03:59:46.028Z",
      "location_count": 5,
      "location_summary": "Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04580134"
    },
    {
      "nct_id": "NCT00065273",
      "title": "Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mental Retardation",
        "Developmental Delay Disorder"
      ],
      "interventions": [
        {
          "name": "risperidone",
          "type": "DRUG"
        },
        {
          "name": "clozapine",
          "type": "DRUG"
        },
        {
          "name": "olanzapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "6 Years to 60 Years"
      },
      "enrollment_count": 50,
      "start_date": "1998-07",
      "completion_date": "2001-06",
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-11-17T03:59:46.028Z",
      "location_count": 1,
      "location_summary": "Lawrence, Kansas",
      "locations": [
        {
          "city": "Lawrence",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00065273"
    },
    {
      "nct_id": "NCT00156637",
      "title": "A Study of Strategies to Improve Schizophrenia Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "Team-Based Quality Improvement Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Opinion Leader Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Team Based Quality Improvement",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 106,
      "start_date": "2005-06",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2015-04-07",
      "last_synced_at": "2026-11-17T03:59:46.028Z",
      "location_count": 4,
      "location_summary": "Fayetteville, Arkansas • No. Little Rock, Arkansas • Dayton, Ohio + 1 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "No. Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Dayton",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00156637"
    },
    {
      "nct_id": "NCT00176436",
      "title": "Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Diet support group",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Group counseling and exercise",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2004-02",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2022-03-14",
      "last_synced_at": "2026-11-17T03:59:46.028Z",
      "location_count": 1,
      "location_summary": "Catonsville, Maryland",
      "locations": [
        {
          "city": "Catonsville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00176436"
    },
    {
      "nct_id": "NCT03857581",
      "title": "Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Psychosis",
        "Substance Use Disorders"
      ],
      "interventions": [
        {
          "name": "Clozapine",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Augusta University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 100,
      "start_date": "2020-07",
      "completion_date": "2021-07",
      "has_results": false,
      "last_update_posted_date": "2020-03-23",
      "last_synced_at": "2026-11-17T03:59:46.028Z",
      "location_count": 1,
      "location_summary": "Evans, Georgia",
      "locations": [
        {
          "city": "Evans",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03857581"
    },
    {
      "nct_id": "NCT03076346",
      "title": "Neural Biomarkers of Clozapine Response",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Schizophrenia",
        "Treatment-resistant Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 41,
      "start_date": "2017-09-01",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-03-06",
      "last_synced_at": "2026-11-17T03:59:46.028Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03076346"
    }
  ]
}